Asset comparator
Compare stocks, ETFs, indices, commodities, cryptocurrencies and bonds over the same period. Indicators that are not meaningful for a given asset type are flagged.
- AstraZeneca
- Bayer
累计表现对比（基数100）
每项资产在2025年10月13日时基数为100；数值120表示自该日起上涨20%（最近共同日期：2026年10月9日）。
Each performance is calculated in the asset's trading currency, without currency conversion.
指标
“不适用”表示该指标对此类资产没有意义：不应进行比较。
| 指标 | AstraZenecaStock | BayerStock |
|---|---|---|
| 业绩与风险 | ||
| Performance over the periodChange in price between the first and last common dates. | −5.7% | +57.7% |
| Annualized performanceAverage annual return that would produce the same total performance. | −5.8% | +58.5% |
| Annualized volatilityTypical range of price movements: the higher it is, the more the price fluctuates. | 26.3% | 42.8% |
| Maximum DrawdownLargest decline from peak to subsequent trough over the period. | −26.3% | −30.9% |
| Sharpe RatioReturn achieved above the risk-free rate (5.24%), per unit of volatility. The higher it is, the better risk was rewarded over the period. | -0.29 | 1.59 |
| 1-day 95% Value at RiskOne-day loss that was exceeded in only 5% of cases (historical VaR). | −2.4% | −3.5% |
| 基本面 | ||
| Market capitalizationTotal market value of all shares (or circulating tokens for a crypto). | 186.08B p | 43B € |
| P/E (trailing 12 months)Share price divided by earnings per share: number of years of earnings paid. | 24.0 | Indisponible |
| Price-to-SalesMarket capitalization divided by annual revenue. | 3.0 | 0.9 |
| Net marginShare of revenue retained as profit. | 17.0% | −3.8% |
| Return on equityReturn on equity (ROE). | 22.0% | −5.7% |
| Revenue growthOver one year, latest published quarter compared with the same quarter of the previous year. | +6.4% | +1.2% |
| Dividend yieldAnnual dividend relative to the share price. | 2.01% | 0.25% |
| Debt / equityFinancial debt relative to shareholders' equity. | 64% | 129% |
期间相关性
取值范围为−1至1：接近1时，两类资产同涨同跌；接近0时，二者走势相互独立。
- AstraZeneca / Bayer0.33
对比分析
由人工智能生成的分析AI 仅根据上述数据比较所选资产，并指出哪些指标不可比。只有在您请求时才会生成文字内容。
以上信息仅供教育参考，不构成投资建议或个性化推荐。过往业绩不预示未来表现。